Afonso et al.26 found that inhibition of necroptosis pharmacologically by Necrostatin-1, a RIP1 inhibitor, or by genetic deletion of RIP3, protected against high-fat choline-deficient (HFCD) diet- or methionine choline-deficient (MCD) diet-induced NAFLD. Here, RIPK1 is linked to metabolic dysfunction-associated steatotic liver disease.